These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 1981981)

  • 41. Recombinant alpha-2a interferon in HIV-associated myelodysplasia.
    Garavelli PL
    Haematologica; 1988; 73(6):547. PubMed ID: 3148520
    [No Abstract]   [Full Text] [Related]  

  • 42. Adjuvant interferon alfa-2b for high-risk melanoma.
    Retsas S
    J Clin Oncol; 1996 Jun; 14(6):1968-9. PubMed ID: 8656272
    [No Abstract]   [Full Text] [Related]  

  • 43. The role of alpha-interferon in multiple myeloma.
    Peest D
    Pathol Biol (Paris); 1999 Feb; 47(2):172-7. PubMed ID: 10192884
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Therapeutic result of operation combined with large-dose of roferon-A for cutaneous malignant melanoma].
    Wang Y; Cen Y; Li Z
    Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2007 Jan; 21(1):37-9. PubMed ID: 17305002
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Alpha interferon approved for AIDS-related Kaposi's sarcoma.
    Oncology (Williston Park); 1989 Jan; 3(1):105. PubMed ID: 2641303
    [No Abstract]   [Full Text] [Related]  

  • 46. [ASCO 2006: temsirolimus increases survival].
    Aktuelle Urol; 2006 Sep; 37(5 Suppl):12. PubMed ID: 23646393
    [No Abstract]   [Full Text] [Related]  

  • 47. Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma.
    Aviles A; Neri N; Fernandez-Diez J; Silva L; Nambo MJ
    Hematology; 2015 Oct; 20(9):538-42. PubMed ID: 25592781
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CML: new biologic therapies, endpoints and questions.
    Martin A; Cheson BD
    Oncology (Williston Park); 1987 Sep; 1(7):12-3, 16. PubMed ID: 3152809
    [No Abstract]   [Full Text] [Related]  

  • 49. [Clinical aspects and treatment of recurrences of lymphosarcoma in children].
    Tselousova OM; Kiselev AV
    Pediatriia; 1991; (11):87-90. PubMed ID: 1766751
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Interferon for melanoma.
    Richtig E; Langmann G
    Ophthalmology; 2010 Sep; 117(9):1861. PubMed ID: 20816255
    [No Abstract]   [Full Text] [Related]  

  • 51. Phase II trial of recombinant alpha-2b interferon in the treatment of metastatic skin melanoma.
    Sertoli MR; Bernengo MG; Ardizzoni A; Brunetti I; Falcone A; Vidili MG; Cusimano MP; Appino A; Doveil G; Fortini C
    Oncology; 1989; 46(2):96-8. PubMed ID: 2710482
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Vindesine-interferon alpha-2b combination in the treatment of metastases of cancer of the kidney].
    Coiffier B; Demolombe S; Tabah I
    Presse Med; 1990 May; 19(21):1009. PubMed ID: 2141143
    [No Abstract]   [Full Text] [Related]  

  • 53. [Role of interferon alfa-2 in melanoma. Results of a phase II study in 27 patients].
    Bernengo MG; Doveil GC; Appino A; Sertoli MR; Ardizzoni A; Vidili MG
    G Ital Dermatol Venereol; 1988 Apr; 123(4):185-8. PubMed ID: 3182009
    [No Abstract]   [Full Text] [Related]  

  • 54. Hematological and cytogenetic response of interferon alpha 2b alone and combined interferon alpha plus cytarabine as a first-line treatment in chronic myeloid leukemia.
    Tóthová E; Fricová M; Kafková A; Stecová N; Guman T; Raffac S; Hlebasková M
    Neoplasma; 2000; 47(2):125-8. PubMed ID: 10985480
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment of stage D2 hormone refractory carcinoma of the prostate with 5-fluorouracil and Roferon-A: a Southwest Oncology Group study.
    Marshall ME; Wolf M; O'Rourke M; Barnett TC; Crawford ED
    Cancer Biother Radiopharm; 1996 Apr; 11(2):119-23. PubMed ID: 10851528
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical prognostic factors in adjuvant melanoma trial.
    Nathanson L
    J Clin Oncol; 1996 Jun; 14(6):1967-8. PubMed ID: 8656271
    [No Abstract]   [Full Text] [Related]  

  • 57. [Assessment of the formation of antibodies to interferon in patients with juvenile respiratory papillomatosis on interferon therapy].
    Kol'tsov VD; Chireshkin DG; Onufrieva EK; Nurmukhametov RKh; Malinovskaia VV; Ershov FI
    Vestn Otorinolaringol; 1996; (4):25-7. PubMed ID: 8966873
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interferon and giant cell tumors.
    Dickerman JD
    Pediatrics; 1999 Jun; 103(6 Pt 1):1282-3. PubMed ID: 10353942
    [No Abstract]   [Full Text] [Related]  

  • 59. Guidelines for the use of Intron A (interferon alfa-2b) in clinical oncology: lessons from the laboratory.
    Smyth JF
    Cancer Treat Rev; 1988 Jan; 15 Suppl A():3-6. PubMed ID: 3342417
    [No Abstract]   [Full Text] [Related]  

  • 60. Reply to Azuaje: Predicting effective combined therapies for heterogeneous tumors.
    Zhao B; Hemann MT; Lauffenburger DA
    Proc Natl Acad Sci U S A; 2014 Oct; 111(41):E4288. PubMed ID: 25253893
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.